Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

DOI Web Site Web Site 被引用文献3件
  • Monique G. P. van der Wijst
    Department of Genetics, University of Groningen, University Medical Center Groningen, 9713AV Groningen, Netherlands.
  • Sara E. Vazquez
    Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.
  • George C. Hartoularos
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Paul Bastard
    Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, 75015 Paris, France.
  • Tianna Grant
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Raymund Bueno
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • David S. Lee
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • John R. Greenland
    Department of Medicine, University of California, San Francisco, San Francisco Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, CA 94121, USA.
  • Yang Sun
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Richard Perez
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Anton Ogorodnikov
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Alyssa Ward
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Sabrina A. Mann
    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Kara L. Lynch
    Zuckerberg San Francisco General, San Francisco, CA 94110, USA.
  • Cassandra Yun
    Zuckerberg San Francisco General, San Francisco, CA 94110, USA.
  • Diane V. Havlir
    Division of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Gabriel Chamie
    Division of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Carina Marquez
    Division of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Bryan Greenhouse
    Division of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Michail S. Lionakis
    Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20814, USA.
  • Philip J. Norris
    Zuckerberg San Francisco General, San Francisco, CA 94110, USA.
  • Larry J. Dumont
    Vitalant Research Institute, Denver, CO 80230, USA.
  • Kathleen Kelly
    Vitalant Research Institute, Denver, CO 80230, USA.
  • Peng Zhang
    St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065, USA.
  • Qian Zhang
    St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065, USA.
  • Adrian Gervais
    University of Paris, Imagine Institute, 75015 Paris, France.
  • Tom Le Voyer
    University of Paris, Imagine Institute, 75015 Paris, France.
  • Alexander Whatley
    Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA 94720, USA.
  • Yichen Si
    Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Ashley Byrne
    Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
  • Alexis J. Combes
    ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Arjun Arkal Rao
    ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Yun S. Song
    Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
  • Gabriela K. Fragiadakis
    Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Kirsten Kangelaris
    Division of Hospital Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Carolyn S. Calfee
    Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine and the Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA.
  • David J. Erle
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Carolyn Hendrickson
    Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine and the Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Matthew F. Krummel
    ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Prescott G. Woodruff
    ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Charles R. Langelier
    Division of Infectious Disease, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Jean-Laurent Casanova
    Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, 75015 Paris, France.
  • Joseph L. Derisi
    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Mark S. Anderson
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Chun Jimmie Ye
    Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.

説明

<jats:p>Type I interferon autoantibodies in patients with COVID-19 are associated with poor interferon responses and increased LAIR1 abundance in leukocytes.</jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

問題の指摘

ページトップへ